South Africa Ends Johnson & Johnson Antitrust Probe After Significant Tuberculosis Drug Price Cuts

South Africa’s antitrust authorities have resolved to terminate their investigation into allegations of anticompetitive behavior by Johnson & Johnson. The inquiry centered on the company’s patent filing for a tuberculosis drug. This decision follows Johnson & Johnson’s commitment to reduce the price of bedaquiline by 40% and to permit the distribution of its generic equivalents in the market. The agreement marks a significant development in improving access to essential medication in the region. For further details on this matter, visit the report by Law360 here.